Original Article

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†

  1. Kathleen Hawker MD1,*,
  2. Paul O'Connor MD2,
  3. Mark S. Freedman MD3,
  4. Peter A. Calabresi MD4,
  5. Jack Antel MD5,
  6. Jack Simon MD6,
  7. Stephen Hauser MD7,
  8. Emmanuelle Waubant MD7,
  9. Timothy Vollmer MD8,
  10. Hillel Panitch MD9,
  11. Jiameng Zhang PhD10,
  12. Peter Chin MD10,
  13. Craig H. Smith MD10

Article first published online: 9 SEP 2009

DOI: 10.1002/ana.21867

Issue

Annals of Neurology

Annals of Neurology

Volume 66, Issue 4, pages 460–471, October 2009

Additional Information

How to Cite

Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., Zhang, J., Chin, P. and Smith, C. H. (2009), Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol., 66: 460–471. doi: 10.1002/ana.21867

Author Information

  1. 1

    Department of Neurology, The Ohio State University Medical Center, Columbus, OH

  2. 2

    Department of Medicine, University of Toronto, Toronto, ON, Canada

  3. 3

    Department of Medicine, Ottawa Hospital-General Campus, Ottawa, ON, Canada

  4. 4

    Department of Neurology, John Hopkins University, Baltimore, MD

  5. 5

    Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada

  6. 6

    Department of Neurology, Portland VA Medical Center, Portland, OR

  7. 7

    Department of Neurology, University of California, San Francisco, San Francisco, CA

  8. 8

    Department of Neurology, University of Colorado, Denver, CO

  9. 9

    Department of Neurology, University of Vermont, Burlington, VT

  10. 10

    Genentech Inc., South San Francisco, San Francisco

*Eli Lilly, 450 South Meridian Street, Indianapolis, IN 46225,

  1. †

    Potential conflict of interest: Dr Hawker has received honoraria from Biogen IDEC, Teva, Bayer, Genentech and GSK; Dr O'Connor has received honoraria from Bio MS, BiogenIDEC, Teva, Serono, Roche, Genentech, Bayer; Dr Freedman has received honoraria from Sanofi-Aventis, BiogenIdec, EMD Serono, Teva, Bayer Healthcare, Eli Lilly, Eisai, Novartis, Genentech; Dr Calabrasi has received honoraria for consulting from: Teva, Biogen-IDEC, Genentech, Serono, Novartis, Amplimmune, Vertex, and Centacor, PC has received research support from Bayer, Serono, Biogen-IDEC, Teva, and Genentech; Dr Waubant's research has been supported by Biogen-Idec, Pfizer, Sanofi-Aventis, the National MS Society, the Immune Tolerance Network and the Nancy Davis Foundation. Dr Waubant has been a consultant for Artielle and Zymogenetics. She has received honorarium for one educational presentation from Biogen Idec; Dr Hauser, Dr Panitch, Dr Vollmer have nothing to disclose.

Publication History

  1. Issue published online: 8 OCT 2009
  2. Article first published online: 9 SEP 2009
  3. Accepted manuscript online: 9 SEP 2009 12:00AM EST
  4. Manuscript Accepted: 1 SEP 2009
  5. Manuscript Revised: 19 AUG 2009
  6. Manuscript Received: 5 AUG 2009

Funded by

  • Clinicaltrials.gov under “A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis”. Grant Number: NCT00087529
  • Genentech, Inc.
  • Biogen Idec, Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (158K)

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
ANA_21867_sm_SupplTab.doc104KSupplemental Table. Demographic Characteristics of Subgroups: Age < 51 and GD negative

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

View Full Article with Supporting Information (HTML) Get PDF (158K)